Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis

David J. Irwin, Murray Grossman, Daniel Weintraub, Howard I. Hurtig, John E. Duda, Sharon X. Xie, Edward B. Lee, Vivianna M. Van Deerlin, Oscar L. Lopez, Julia K. Kofler, Peter T. Nelson, Gregory A. Jicha, Randall (Randy) Woltjer, Joseph Quinn, Jeffrey Kaye, James B. Leverenz, Debby Tsuang, Katelan Longfellow, Dora Yearout, Walter KukullC. Dirk Keene, Thomas J. Montine, Cyrus P. Zabetian, John Q. Trojanowski

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Background Great heterogeneity exists in survival and the interval between onset of motor symptoms and dementia symptoms across synucleinopathies. We aimed to identify genetic and pathological markers that have the strongest association with these features of clinical heterogeneity in synucleinopathies. Methods In this retrospective study, we examined symptom onset, and genetic and neuropathological data from a cohort of patients with Lewy body disorders with autopsy-confirmed α synucleinopathy (as of Oct 1, 2015) who were previously included in other studies from five academic institutions in five cities in the USA. We used histopathology techniques and markers to assess the burden of tau neurofibrillary tangles, neuritic plaques, α-synuclein inclusions, and other pathological changes in cortical regions. These samples were graded on an ordinal scale and genotyped for variants associated with synucleinopathies. We assessed the interval from onset of motor symptoms to onset of dementia, and overall survival in groups with varying levels of comorbid Alzheimer's disease pathology according to US National Institute on Aging–Alzheimer's Association neuropathological criteria, and used multivariate regression to control for age at death and sex. Findings On the basis of data from 213 patients who had been followed up to autopsy and met inclusion criteria of Lewy body disorder with autopsy-confirmed α synucleinopathy, we identified 49 (23%) patients with no Alzheimer's disease neuropathology, 56 (26%) with low-level Alzheimer's disease neuropathology, 45 (21%) with intermediate-level Alzheimer's disease neuropathology, and 63 (30%) with high-level Alzheimer's disease neuropathology. As levels of Alzheimer's disease neuropathology increased, cerebral α-synuclein scores were higher, and the interval between onset of motor and dementia symptoms and disease duration was shorter (p<0·0001 for all comparisons). Multivariate regression showed independent negative associations of cerebral tau neurofibrillary tangles score with the interval between onset of motor and dementia symptoms (β −4·0, 95% CI −5·5 to −2·6; p<0·0001; R2 0·22, p<0·0001) and with survival (–2·0, −3·2 to −0·8; 0·003; 0·15, <0·0001) in models that included age at death, sex, cerebral neuritic plaque scores, cerebral α-synuclein scores, presence of cerebrovascular disease, MAPT haplotype, and APOE genotype as covariates. Interpretation Alzheimer's disease neuropathology is common in synucleinopathies and confers a worse prognosis for each increasing level of neuropathological change. Cerebral neurofibrillary tangles burden, in addition to α-synuclein pathology and amyloid plaque pathology, are the strongest pathological predictors of a shorter interval between onset of motor and dementia symptoms and survival. Diagnostic criteria based on reliable biomarkers for Alzheimer's disease neuropathology in synucleinopathies should help to identify the most appropriate patients for clinical trials of emerging therapies targeting tau, amyloid-β or α synuclein, and to stratify them by level of Alzheimer's disease neuropathology. Funding US National Institutes of Health (National Institute on Aging and National Institute of Neurological Disorders and Stroke).

Original languageEnglish (US)
Pages (from-to)1234
Number of pages1
JournalThe Lancet Neurology
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Dementia
Synucleins
Alzheimer Disease
Survival
Neurofibrillary Tangles
Amyloid Plaques
Lewy Bodies
Autopsy
Pathology
National Institute on Aging (U.S.)
National Institute of Neurological Disorders and Stroke
Cerebrovascular Disorders
Neuropathology
National Institutes of Health (U.S.)
Genetic Markers
Amyloid
Haplotypes
Retrospective Studies
Biomarkers
Genotype

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Irwin, D. J., Grossman, M., Weintraub, D., Hurtig, H. I., Duda, J. E., Xie, S. X., ... Trojanowski, J. Q. (2017). Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. The Lancet Neurology, 16(1), 1234. https://doi.org/10.1016/S1474-4422(16)30291-5

Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies : a retrospective analysis. / Irwin, David J.; Grossman, Murray; Weintraub, Daniel; Hurtig, Howard I.; Duda, John E.; Xie, Sharon X.; Lee, Edward B.; Van Deerlin, Vivianna M.; Lopez, Oscar L.; Kofler, Julia K.; Nelson, Peter T.; Jicha, Gregory A.; Woltjer, Randall (Randy); Quinn, Joseph; Kaye, Jeffrey; Leverenz, James B.; Tsuang, Debby; Longfellow, Katelan; Yearout, Dora; Kukull, Walter; Keene, C. Dirk; Montine, Thomas J.; Zabetian, Cyrus P.; Trojanowski, John Q.

In: The Lancet Neurology, Vol. 16, No. 1, 01.01.2017, p. 1234.

Research output: Contribution to journalArticle

Irwin, DJ, Grossman, M, Weintraub, D, Hurtig, HI, Duda, JE, Xie, SX, Lee, EB, Van Deerlin, VM, Lopez, OL, Kofler, JK, Nelson, PT, Jicha, GA, Woltjer, RR, Quinn, J, Kaye, J, Leverenz, JB, Tsuang, D, Longfellow, K, Yearout, D, Kukull, W, Keene, CD, Montine, TJ, Zabetian, CP & Trojanowski, JQ 2017, 'Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis', The Lancet Neurology, vol. 16, no. 1, pp. 1234. https://doi.org/10.1016/S1474-4422(16)30291-5
Irwin, David J. ; Grossman, Murray ; Weintraub, Daniel ; Hurtig, Howard I. ; Duda, John E. ; Xie, Sharon X. ; Lee, Edward B. ; Van Deerlin, Vivianna M. ; Lopez, Oscar L. ; Kofler, Julia K. ; Nelson, Peter T. ; Jicha, Gregory A. ; Woltjer, Randall (Randy) ; Quinn, Joseph ; Kaye, Jeffrey ; Leverenz, James B. ; Tsuang, Debby ; Longfellow, Katelan ; Yearout, Dora ; Kukull, Walter ; Keene, C. Dirk ; Montine, Thomas J. ; Zabetian, Cyrus P. ; Trojanowski, John Q. / Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies : a retrospective analysis. In: The Lancet Neurology. 2017 ; Vol. 16, No. 1. pp. 1234.
@article{95e11d22c0884f589481d75987fbcca8,
title = "Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis",
abstract = "Background Great heterogeneity exists in survival and the interval between onset of motor symptoms and dementia symptoms across synucleinopathies. We aimed to identify genetic and pathological markers that have the strongest association with these features of clinical heterogeneity in synucleinopathies. Methods In this retrospective study, we examined symptom onset, and genetic and neuropathological data from a cohort of patients with Lewy body disorders with autopsy-confirmed α synucleinopathy (as of Oct 1, 2015) who were previously included in other studies from five academic institutions in five cities in the USA. We used histopathology techniques and markers to assess the burden of tau neurofibrillary tangles, neuritic plaques, α-synuclein inclusions, and other pathological changes in cortical regions. These samples were graded on an ordinal scale and genotyped for variants associated with synucleinopathies. We assessed the interval from onset of motor symptoms to onset of dementia, and overall survival in groups with varying levels of comorbid Alzheimer's disease pathology according to US National Institute on Aging–Alzheimer's Association neuropathological criteria, and used multivariate regression to control for age at death and sex. Findings On the basis of data from 213 patients who had been followed up to autopsy and met inclusion criteria of Lewy body disorder with autopsy-confirmed α synucleinopathy, we identified 49 (23{\%}) patients with no Alzheimer's disease neuropathology, 56 (26{\%}) with low-level Alzheimer's disease neuropathology, 45 (21{\%}) with intermediate-level Alzheimer's disease neuropathology, and 63 (30{\%}) with high-level Alzheimer's disease neuropathology. As levels of Alzheimer's disease neuropathology increased, cerebral α-synuclein scores were higher, and the interval between onset of motor and dementia symptoms and disease duration was shorter (p<0·0001 for all comparisons). Multivariate regression showed independent negative associations of cerebral tau neurofibrillary tangles score with the interval between onset of motor and dementia symptoms (β −4·0, 95{\%} CI −5·5 to −2·6; p<0·0001; R2 0·22, p<0·0001) and with survival (–2·0, −3·2 to −0·8; 0·003; 0·15, <0·0001) in models that included age at death, sex, cerebral neuritic plaque scores, cerebral α-synuclein scores, presence of cerebrovascular disease, MAPT haplotype, and APOE genotype as covariates. Interpretation Alzheimer's disease neuropathology is common in synucleinopathies and confers a worse prognosis for each increasing level of neuropathological change. Cerebral neurofibrillary tangles burden, in addition to α-synuclein pathology and amyloid plaque pathology, are the strongest pathological predictors of a shorter interval between onset of motor and dementia symptoms and survival. Diagnostic criteria based on reliable biomarkers for Alzheimer's disease neuropathology in synucleinopathies should help to identify the most appropriate patients for clinical trials of emerging therapies targeting tau, amyloid-β or α synuclein, and to stratify them by level of Alzheimer's disease neuropathology. Funding US National Institutes of Health (National Institute on Aging and National Institute of Neurological Disorders and Stroke).",
author = "Irwin, {David J.} and Murray Grossman and Daniel Weintraub and Hurtig, {Howard I.} and Duda, {John E.} and Xie, {Sharon X.} and Lee, {Edward B.} and {Van Deerlin}, {Vivianna M.} and Lopez, {Oscar L.} and Kofler, {Julia K.} and Nelson, {Peter T.} and Jicha, {Gregory A.} and Woltjer, {Randall (Randy)} and Joseph Quinn and Jeffrey Kaye and Leverenz, {James B.} and Debby Tsuang and Katelan Longfellow and Dora Yearout and Walter Kukull and Keene, {C. Dirk} and Montine, {Thomas J.} and Zabetian, {Cyrus P.} and Trojanowski, {John Q.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/S1474-4422(16)30291-5",
language = "English (US)",
volume = "16",
pages = "1234",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies

T2 - a retrospective analysis

AU - Irwin, David J.

AU - Grossman, Murray

AU - Weintraub, Daniel

AU - Hurtig, Howard I.

AU - Duda, John E.

AU - Xie, Sharon X.

AU - Lee, Edward B.

AU - Van Deerlin, Vivianna M.

AU - Lopez, Oscar L.

AU - Kofler, Julia K.

AU - Nelson, Peter T.

AU - Jicha, Gregory A.

AU - Woltjer, Randall (Randy)

AU - Quinn, Joseph

AU - Kaye, Jeffrey

AU - Leverenz, James B.

AU - Tsuang, Debby

AU - Longfellow, Katelan

AU - Yearout, Dora

AU - Kukull, Walter

AU - Keene, C. Dirk

AU - Montine, Thomas J.

AU - Zabetian, Cyrus P.

AU - Trojanowski, John Q.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background Great heterogeneity exists in survival and the interval between onset of motor symptoms and dementia symptoms across synucleinopathies. We aimed to identify genetic and pathological markers that have the strongest association with these features of clinical heterogeneity in synucleinopathies. Methods In this retrospective study, we examined symptom onset, and genetic and neuropathological data from a cohort of patients with Lewy body disorders with autopsy-confirmed α synucleinopathy (as of Oct 1, 2015) who were previously included in other studies from five academic institutions in five cities in the USA. We used histopathology techniques and markers to assess the burden of tau neurofibrillary tangles, neuritic plaques, α-synuclein inclusions, and other pathological changes in cortical regions. These samples were graded on an ordinal scale and genotyped for variants associated with synucleinopathies. We assessed the interval from onset of motor symptoms to onset of dementia, and overall survival in groups with varying levels of comorbid Alzheimer's disease pathology according to US National Institute on Aging–Alzheimer's Association neuropathological criteria, and used multivariate regression to control for age at death and sex. Findings On the basis of data from 213 patients who had been followed up to autopsy and met inclusion criteria of Lewy body disorder with autopsy-confirmed α synucleinopathy, we identified 49 (23%) patients with no Alzheimer's disease neuropathology, 56 (26%) with low-level Alzheimer's disease neuropathology, 45 (21%) with intermediate-level Alzheimer's disease neuropathology, and 63 (30%) with high-level Alzheimer's disease neuropathology. As levels of Alzheimer's disease neuropathology increased, cerebral α-synuclein scores were higher, and the interval between onset of motor and dementia symptoms and disease duration was shorter (p<0·0001 for all comparisons). Multivariate regression showed independent negative associations of cerebral tau neurofibrillary tangles score with the interval between onset of motor and dementia symptoms (β −4·0, 95% CI −5·5 to −2·6; p<0·0001; R2 0·22, p<0·0001) and with survival (–2·0, −3·2 to −0·8; 0·003; 0·15, <0·0001) in models that included age at death, sex, cerebral neuritic plaque scores, cerebral α-synuclein scores, presence of cerebrovascular disease, MAPT haplotype, and APOE genotype as covariates. Interpretation Alzheimer's disease neuropathology is common in synucleinopathies and confers a worse prognosis for each increasing level of neuropathological change. Cerebral neurofibrillary tangles burden, in addition to α-synuclein pathology and amyloid plaque pathology, are the strongest pathological predictors of a shorter interval between onset of motor and dementia symptoms and survival. Diagnostic criteria based on reliable biomarkers for Alzheimer's disease neuropathology in synucleinopathies should help to identify the most appropriate patients for clinical trials of emerging therapies targeting tau, amyloid-β or α synuclein, and to stratify them by level of Alzheimer's disease neuropathology. Funding US National Institutes of Health (National Institute on Aging and National Institute of Neurological Disorders and Stroke).

AB - Background Great heterogeneity exists in survival and the interval between onset of motor symptoms and dementia symptoms across synucleinopathies. We aimed to identify genetic and pathological markers that have the strongest association with these features of clinical heterogeneity in synucleinopathies. Methods In this retrospective study, we examined symptom onset, and genetic and neuropathological data from a cohort of patients with Lewy body disorders with autopsy-confirmed α synucleinopathy (as of Oct 1, 2015) who were previously included in other studies from five academic institutions in five cities in the USA. We used histopathology techniques and markers to assess the burden of tau neurofibrillary tangles, neuritic plaques, α-synuclein inclusions, and other pathological changes in cortical regions. These samples were graded on an ordinal scale and genotyped for variants associated with synucleinopathies. We assessed the interval from onset of motor symptoms to onset of dementia, and overall survival in groups with varying levels of comorbid Alzheimer's disease pathology according to US National Institute on Aging–Alzheimer's Association neuropathological criteria, and used multivariate regression to control for age at death and sex. Findings On the basis of data from 213 patients who had been followed up to autopsy and met inclusion criteria of Lewy body disorder with autopsy-confirmed α synucleinopathy, we identified 49 (23%) patients with no Alzheimer's disease neuropathology, 56 (26%) with low-level Alzheimer's disease neuropathology, 45 (21%) with intermediate-level Alzheimer's disease neuropathology, and 63 (30%) with high-level Alzheimer's disease neuropathology. As levels of Alzheimer's disease neuropathology increased, cerebral α-synuclein scores were higher, and the interval between onset of motor and dementia symptoms and disease duration was shorter (p<0·0001 for all comparisons). Multivariate regression showed independent negative associations of cerebral tau neurofibrillary tangles score with the interval between onset of motor and dementia symptoms (β −4·0, 95% CI −5·5 to −2·6; p<0·0001; R2 0·22, p<0·0001) and with survival (–2·0, −3·2 to −0·8; 0·003; 0·15, <0·0001) in models that included age at death, sex, cerebral neuritic plaque scores, cerebral α-synuclein scores, presence of cerebrovascular disease, MAPT haplotype, and APOE genotype as covariates. Interpretation Alzheimer's disease neuropathology is common in synucleinopathies and confers a worse prognosis for each increasing level of neuropathological change. Cerebral neurofibrillary tangles burden, in addition to α-synuclein pathology and amyloid plaque pathology, are the strongest pathological predictors of a shorter interval between onset of motor and dementia symptoms and survival. Diagnostic criteria based on reliable biomarkers for Alzheimer's disease neuropathology in synucleinopathies should help to identify the most appropriate patients for clinical trials of emerging therapies targeting tau, amyloid-β or α synuclein, and to stratify them by level of Alzheimer's disease neuropathology. Funding US National Institutes of Health (National Institute on Aging and National Institute of Neurological Disorders and Stroke).

UR - http://www.scopus.com/inward/record.url?scp=85004140744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004140744&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(16)30291-5

DO - 10.1016/S1474-4422(16)30291-5

M3 - Article

C2 - 27979356

AN - SCOPUS:85004140744

VL - 16

SP - 1234

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 1

ER -